Interestingly, as can be observed in Fig. 3D, the Valine, Leucine and Isoleucine (branched amino acids) degradation pathway is not interconnected with the key metabolic aberrations observed in GSD1a and DLDD (one‐carbon related pathways), suggesting that it might stand alone also as a therapeutic target unrelated to one‐carbon metabolism. This evidence concerns the gene G6PC1 and pyruvate dehydrogenase E3 deficiency.